Prosecution Insights
Last updated: April 19, 2026
Application No. 18/035,711

METHOD FOR OBTAINING AQUEOUS EXTRACTS OF TEA LEAVES, COMPOSITIONS COMPRISING SUCH EXTRACTS AND COSMETIC USES THEREOF

Non-Final OA §112§DP
Filed
May 05, 2023
Examiner
OLSEN, KAELEIGH ELIZABETH
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Isp Investments LLC
OA Round
1 (Non-Final)
38%
Grant Probability
At Risk
1-2
OA Rounds
3y 4m
To Grant
99%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allow Rate
6 granted / 16 resolved
-22.5% vs TC avg
Strong +71% interview lift
Without
With
+71.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
61 currently pending
Career history
77
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
42.5%
+2.5% vs TC avg
§102
8.6%
-31.4% vs TC avg
§112
33.9%
-6.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 16 resolved cases

Office Action

§112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Formal Matters Claims 1-13 are pending. Election/Restriction Applicant’s election without traverse of Group I, claims 1-7, in the reply filed on 01/06/2026 is acknowledged. Applicant also elected the following in the reply filed on 01/06/2026: Pu’er tea as the species of tea leaves; and Butylene glycol as the species of physiologically acceptable solvent. Claims 8-13 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-7 are being examined to the extent of the elected species, i.e., the tea leaves are pu’er tea and the physiologically acceptable solvent is butylene glycol. Priority This application is a 371 of PCT/EP2021/082631 filed 11/23/2021, claiming priority to FR 2012019 filed 11/23/2020. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statements (IDS) filed 05/05/2023 and 01/06/2026 have been considered by the Examiner. A signed copy of each IDS is included with the present Office Action. In the IDS filed 05/05/2023, Foreign Patent Document Cite No. 7 is lined through because there is no document in the case file corresponding to WO 2020/089831 A1 with the publication date of 08/12/2021 by ISP Investments LLC/Oger Elodie. Instead, there is a document in the case file corresponding to WO 2021/156104 A1 with the publication date of 08/12/2021 by ISP Investments LLC/Oger Elodie. Claim Objections Claims 1 is objected to because of the following: In line 6 of claim 1, a space should be added between “80” and the degree symbol for grammatical correctness; In line 7 of claim 1, the period appearing before the semicolon should be deleted to improve claim readability; and In claim 1, either remove “(PVPP)” from line 13 or replace “polyvinylpolypyrrolidones” in line 14 with “PVPP” for proper use of the abbreviation and to improve claim readability. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. (a) Claim 1 is indefinite in the recitation of “tea leaves (Camellia sinensis)” in line 1 because the use of parentheticals makes it is unclear whether ‘Camellia sinensis’ is merely an exemplary embodiment and not required by the claim, or whether ‘Camellia sinensis’ is a further limitation and required, or whether something else is meant by the parentheticals. Claims 2-7 are rejected for depending from claim 1 without resolving the ambiguity. (b) Claim 1 is indefinite in the recitation of “and then possibly crushing them” in line 3 because it is unclear whether ‘and then crushing them’ is a part of the claimed invention. See MPEP § 2173.05(d). Claims 2-7 are rejected for depending from claim 1 without resolving the ambiguity. (c) A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 2 recites the broad recitation “ratio of 3% to 20% w/w” and also recites the narrower statement of the range/limitation “preferably in a ratio between 3% and 10%”. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. (d) Claim 3 is indefinite in the recitation of “between 1 and mM” in line 2 because it is unclear what range is meant by this phrase. (e) A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 3 recites the broad recitation (and indefinite recitation; see (d) above) “between 1 and mM” and also recites the narrower statement of the range/limitation “preferably between 1 and 5 mM”. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. (f) A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 6 recites the broad recitation “between 5.8 and 6.5” and also recites the narrower statement of the range/limitation “preferably between 6.0 and 6.5”. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claim 7 is rejected for depending on claim 6 without resolving the ambiguity. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-7 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 6-11 of copending Application No. 18/291,098 (reference application; hereafter ‘098). Although the claims at issue are not identical, they are not patentably distinct from each other because the process recited in claims 6-11 of ‘098 is the same process recited in instant claims 1-7. Specifically, Instant claims 1 and 6 are met by claim 6 of ‘098. Instant claim 2 is met by claim 8 of ‘098. Instant claim 3 is met by claim 9 of ‘098. Instant claim 4 is met by claim 10 of ‘098. Instant claim 5 is met by claim 11 of ‘098. Instant claim 7 is met by claim 7 of ‘098. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion No claims are allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAELEIGH ELIZABETH OLSEN whose telephone number is (703)756-1962. The examiner can normally be reached M-F 8-5 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Blanchard can be reached at (571)272-0827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /K.E.O./ Examiner, Art Unit 1619 /NICOLE P BABSON/Primary Examiner, Art Unit 1619
Read full office action

Prosecution Timeline

May 05, 2023
Application Filed
Mar 17, 2026
Non-Final Rejection — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599129
FORMULATION AND COMPOSITION WHICH PROMOTE TARGETED POLLINATION BY BEES TOWARDS BLUEBERRY CROPS AND RELATED METHODS
2y 5m to grant Granted Apr 14, 2026
Patent 12582116
AGRICULTURAL FORMULATIONS
2y 5m to grant Granted Mar 24, 2026
Patent 12521325
FRAGRANCE COMPOSITION, SCENT DISPENSER AND METHOD FOR REDUCING MALODOR
2y 5m to grant Granted Jan 13, 2026
Patent 12471593
Methods and Compositions for Controlling Tomato Leaf Miner, Tuta absoluta
2y 5m to grant Granted Nov 18, 2025
Patent 12318474
COSMETIC COMPOSITION COMPRISING DEAD LACTIC ACID BACTERIA LACTOBACILLUS PLANTARUM MASS OR CULTURE OF LACTIC ACID BACTERIA FOR PREVENTING OR ALLEVIATING SKIN AGING
2y 5m to grant Granted Jun 03, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
38%
Grant Probability
99%
With Interview (+71.4%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 16 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month